Combination of the PAK1 inhibitor, FRAX597, with gemcitabine resulted in increased inhibition of PAK1 activity in some, but not all, of the pancreatic cancer cell lines tested (Fig. 6a-e). Here, PAK1 is linked to pancreatic neoplasm.